Alleyba says.......................... ........

Alleyba says..........................

................that was an excellent post. The core risked their OWN money and took the risk with all of those deterents out there and also not knowing what, if any, stumbling blocks or roadblocks were ahead of them. The CORE put their faith in the revised business model (compounding), the existing model Rapmeds, the relatively new RX and let it all play out.

It appears their patience is about to be rewarded as the compounding numbers are excellent and SCRC should do $10-$12 million this quarter in compounding alone, the Rapimeds order should be shipped in the near future in my opinion which is a $200,000 order which is substantiaal profit margin which will open the flood gates in Asian market, and the RX should add to the bottom line so the $10-$12 million should result in bigger number for 3rd quarter which makes this company cash positive and catches the eye of Wall Street.

The playbook has been scripted very nicely and SCRC appears ready to hit on ALL CYLINDERS. Oops Alleyba forgot to mention PIMD and expansion into other states..........more revenue streams.